William Blair Investment Management LLC increased its position in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 29.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 832,881 shares of the biotechnology company’s stock after buying an additional 190,705 shares during the quarter. William Blair Investment Management LLC’s holdings in Innoviva were worth $17,665,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Fortitude Family Office LLC purchased a new position in shares of Innoviva in the third quarter valued at about $25,000. Parallel Advisors LLC grew its holdings in shares of Innoviva by 82.8% in the first quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 534 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Innoviva in the 2nd quarter worth $30,000. Versant Capital Management Inc increased its holdings in shares of Innoviva by 96.5% in the 3rd quarter. Versant Capital Management Inc now owns 1,916 shares of the biotechnology company’s stock worth $41,000 after buying an additional 941 shares during the last quarter. Finally, Allworth Financial LP purchased a new stake in shares of Innoviva during the 2nd quarter valued at about $42,000. Institutional investors own 99.12% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently commented on INVA. Wall Street Zen lowered Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Oppenheimer cut their target price on Innoviva from $35.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Cantor Fitzgerald lowered their target price on shares of Innoviva from $36.00 to $34.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Zacks Research raised shares of Innoviva from a “strong sell” rating to a “hold” rating in a research note on Monday, August 31st. Finally, Weiss Ratings raised Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a research note on Monday, November 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Innoviva has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.
Get Our Latest Stock Analysis on Innoviva
Innoviva Stock Performance
Shares of Innoviva stock opened at $19.03 on Monday. The company has a current ratio of 15.44, a quick ratio of 14.58 and a debt-to-equity ratio of 0.23. The firm’s 50 day simple moving average is $20.70 and its two-hundred day simple moving average is $21.85. Innoviva, Inc. has a 12-month low of $18.66 and a 12-month high of $25.15. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.56, a PEG ratio of 4.16 and a beta of 0.38.
Innoviva (NASDAQ:INVA – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($1.55). The firm had revenue of $106.12 million for the quarter, compared to analyst estimates of $115.31 million. Innoviva had a return on equity of 22.91% and a net margin of 44.13%. Analysts predict that Innoviva, Inc. will post 1.52 EPS for the current year.
Innoviva Profile
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
Featured Articles
- Five stocks we like better than Innoviva
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVA – Free Report).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
